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Abstract 
Background: Patients with HIV mono-infection may develop chronic liver disease due to a number 
of factors including hepatic steatosis. We estimated prevalence and predictors of hepatic steatosis 
and fibrosis in a cohort of HIV mono-infected patients with persistently deranged LFTs.  
Methods: Out of 2398 consecutive patients at one UK clinical centre, 156 (6.5%) had persistently 
abnormal transaminases in at least two measurements six months apart. We used APRI and FIB4 
scores to determine the presence of significant and/or advanced fibrosis in this group and potential 
associations. 
Results and Conclusions: Mean age was 47.5±8.5 years and 91% (142/156) were males. Diabetes 
(DM) was present in 11% of, hypertension in 18% and dyslipidemia in 52%. Almost all were on 
antiretroviral therapy (ART) (97%) and most were virologically suppressed (94%).  Steatosis was 
detected at ultrasound in 71% of patients. Prevalence of FIB4≤1.45, 1.46-3.24 and >3.25 was 67%, 
29% and 4% respectively, and of APRI≤0.5, 0.51-1.49 and >1.5 was 52%, 45% and 3% respectively. 
In multivariate analysis, only cumulative ART exposure was associated with FIB4>1.45 (OR 1.008, 
95%CI 1.000-1.016) while APRI>0.5 was associated with higher ALT levels (OR 1.033, 95%CI 1.015-
1.510). Twenty patients had a liver biopsy, of whom 13 had non-alcoholic fatty liver disease (NAFLD).  
Elevated transaminases are often present in HIV mono-infected patients and this may be associated 
with NAFLD and/or ART. Non-invasive screening for the presence of NAFLD and fibrosis to all HIV 
mono-infected patients as part of their routine clinical management should be further explored. 
Introduction 
In the era of effective antiretroviral therapy (ART), chronic liver disease is an important cause of 
morbidity and mortality among HIV-positive people, even in the absence of HCV and HBV co-
infections [1, 2].  
Mild transaminitis in HIV-positive individuals on ART is frequently reported [3], although the 
aetiology is often indeterminate. In a study by Crum-Cianflone, elevated transaminases were found 
in 80 (27%) of 299 HIV mono-infected patients on ART and steatosis detected on ultrasound in 30%, 
though in 51% the cause of liver dysfunction remained unexplained [4]. 
Fatty liver due to metabolic syndrome and/or ART exposure is an increasingly recognized cause of 
liver test abnormality in HIV mono-infected patients [3]. Non-alcoholic fatty liver disease (NAFLD) is 
the hepatic manifestation of metabolic syndrome (MS) [5], but could also represent a long-term 
toxicity of ART as nucleoside reverse-transcriptase inhibitors (NRTIs) and to a lesser extent protease 
inhibitors (PIs), are associated with insulin resistance and mitochondrial toxicity [6]. Moreover, 
specific HIV-related factors may predispose to NAFLD, such as lipodistrophy or the HIV virus per se 
[7, 8]. NAFLD has a prevalence of 20% in the general population of industrialized countries, which 
rises to more than 50% in HIV infected people [9]. 
Since NAFLD encompasses a wide spectrum of disease ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis [10], the early detection of liver 
fibrosis prior to onset of complications associated with decompensated liver disease is crucial. Non-
invasive fibrosis tests are increasingly used for the assessment of fibrosis in patients with liver 
disease [11], including in HIV positive people [12]. 
In this study, we retrospectively evaluated the prevalence and predictors of liver fibrosis in a cohort 
of HIV mono-infected patients with persistently elevated transaminases by using simple serum non-
invasive fibrosis panels, namely FIB4 and APRI index. Moreover, we assessed the presence of hepatic 
steatosis and associated features in this cohort. 
Material and Methods 
Study population 
This is a retrospective cross-sectional audit of consecutive HIV mono-infected patients that attended 
the HIV dedicated outpatient service at Royal Free Hospital, London, UK, from January to December 
2014. A clinical database was used to identify patients with persistently elevated transaminases in 
at least two measurements six months apart. Serum levels more than 39 IU/L and 41 IU/L were 
considered as abnormal for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 
respectively. Patients with evidence of HCV or HBV co-infection, as well as other documented causes 
of liver disease other than NAFLD were excluded. Further information for patients with persistently 
abnormal transaminases was retrieved from their clinical notes. 
Laboratory investigations and epidemiological and clinical features were retrieved from the clinical 
database for all included patients. The presence of diabetes, hypertension and dyslipidemia, as well 
as relevant medications were documented. 
HIV specific information was also obtained; this included time since diagnosis, duration of ART, most 
recent CD4+ count(n/mm3) and HIV viral load (RNA copies/mm3). HIV RNA copies <40/mmc defined 
virologic suppression. 
Liver fibrosis and steatosis assessment 
We obtained the results of abdominal ultrasound scans and transient elastography (TE) with 
Fibroscan® which were performed as part of the routine clinical care to further investigate the liver 
test abnormalities and stage fibrosis respectively. US and TE was included if within 6 months of the 
date of transaminase measurement. 
The presence of significant (≥F2 METAVIR stage) or advanced (≥F3 METAVIR stage) liver fibrosis was 
evaluated by APRI and FIB4 scores respectively. APRI consists of AST and platelet count in the 
formula [AST levels (IU/L)/AST ULN (IU/L)/Platelets (10^9/L)]*100 and It has dual cut-offs for ruling 
out (<0.5) or diagnosing (>1.5) significant fibrosis[13]. FIB4 consists of age, AST, ALT and platelet 
count in the formula [( Age (years) x AST (IU/L)) / (Platelets (10^9/L)*√ALT (IU/L))]and it also has dual 
cut-offs and for ruling out (<1.45) or diagnosing (>3.25) advanced fibrosis [14]. These tests usually 
have dual cut-offs: a high cut-off with high specificity and a low cut-off with high sensitivity. 
Depending on the clinical scenario and the disease prevalence, the low or high cut-off is used at the 
expense of increased false positives and false negatives respectively. If these cut-offs are combined, 
then the number of false positive and false negatives are minimized, however, a number of patients 
will fall in the indeterminate range of fibrosis (i.e. their score will be indeterminate ie between the 
low and the high cut-off) and will need either further non-invasive testing or a liver biopsy [15]. 
In a small subgroup of 19 patients, transient elastography (TE) was performed with 
FibroScan®(Echosens; Paris, France), after at least 6 hours of fasting. Results in Kilopascals (KPa), 
were calculated as the mean of ten valid measurements, obtained by placing the probe on the 
patient’s skin between the ribs at the level of the right lobe of the liver in dorsal decubitus position. 
Only determinations of liver stiffness with an interquartile range for measurements within 30% and 
ratio of success rate of measurements (number of total measurements/number of valid acquisition) 
>60% were considered reliable. Liver stiffness values >7.4 kPa were considered suggestive of 
significant fibrosis.  
Finally, 20 patients in the same cohort had previous liver biopsies as part of their routine clinical 
care. The presence and severity of steatosis, as well as histological grading and staging were 
assessed according to the Brunt score [16].  
Statistical analysis 
All data were analysed using the statistical package SPSS (version 22.0, IBM, New York, NY, USA). 
Statistical analysis was performed using t-test, ANOVA, Mann-Whitney test or Kruskal-Wallis test 
for comparisons of continuous variables between or among groups, corrected chi-squared method 
or two-tailed Fisher’s exact test for comparisons of qualitative data and Spearman’s co-efficient for 
correlations of quantitative data, when appropriate. Multivariate analysis was performed using 
logistic regression models to assess predictors of steatosis and fibrosis with APRI and FIB-4 values 
of >0.5 and >1.45 respectively. Only variables with a P value 0.10 at univariate analysis were 
entered in the multivariate analysis models. A two-tailed P value <0.05 was considered to indicate 
a statistically significant difference between groups. 
Results 
Baseline characteristics 
Out of 2398 consecutive patients with HIV mono-infection between January and December 2014, 
156 (6.5%) had persistently elevated transaminases in at least two measurements six months apart 
and were included in the analysis. 
The mean age of those included was 47.5 years and 91% were males. Clinical, biochemical and 
virological characteristics are reported in Table 1. In particular, 28 patients (17.9%) had 
hypertension, 17 (10.9%) had diabetes and 80 (51.9%) had hyperlipidaemia, while 47 (30.5%) were 
on lipid-lowering medication. 
AST and ALT values <2 times upper limit of normal (ULN) were found in 93.6% and 81.4% of patients 
respectively, 2-3 times ULN in at least one measurement in 3.8% and 14.1% and >3 times ULN in at 
least one measurement in 2.6% and 4.5% of the cohort.  
Almost all patients were on ART (n= 154, 97%), with a median length of treatment of 11 years (IQR 
0-26 years), and the majority of them had virological suppression (n=146, 93.6%). Mean time since 
diagnosis was 14 years (IQR 2-30 years). CD4 counts <200/mm3 were present only in 3 (1.9%) 
patients and median viral load was 39 copies/mm3 (IQR 39-2622).  
Information about the specific treatment regimen were available only in 97 patients. The most 
common drugs used were NRTIs in 86 (88.7%) of treated patients, while PIs and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) were prescribed in 41 (42.3%) and 46 (47.4%) of patients, 
respectively.  
Prevalence and predictors of hepatic steatosis 
Ultrasound examination was performed in 66 (42.3%) patients, and fatty liver was detected in the 
majority of these (n=47, 71.2%) as shown in table 2. Nevertheless, no association was found 
between the presence of US steatosis and patients’ clinical features, as shown in table 3. In 
particular, there was no association between the presence of steatosis and metabolic features, 
namely hypertension, diabetes and dyslipidemia. Importantly, fatty liver was not significantly 
associated with the since diagnosis, the length of ART, or the category of the antiviral drugs used. 
At univariate analysis, fenofibrate use was significantly associated with the absence of US steatosis 
(p=0.022), but this association was lost in the multivariate model.  
 
Prevalence and predictors of significant and advanced liver fibrosis 
Considering the high cut-off of >1.5 for APRI, we categorised 5 (3.2%) patients as having significant 
fibrosis (≥F2), whereas values <0.5 excluded this diagnosis in 51.9% of them. On the other hand, 
FIB4>3.25 suggested advanced fibrosis (≥F3) in 6 (3.8%) patients while values ≤1.45 (<F3) were 
found in 67.3% of the cohort. Forty-five (28.8%) and 70 (44.9%) patients fell into the 
“indeterminate” diagnostic zone of FIB4 and APRI, respectively, as shown in table 2.  
For further analysis, and in keeping with the use of NITs as screening tests, we considered a 
threshold of 1.45 for FIB4 and of 0.5 of APRI to rule out the presence of advanced or significant 
fibrosis respectively in our cohort of HIV mono-infected patients.   
In univariate analysis, FIB4 >1.45 (n=51, 32.7%), was significantly associated with both time since 
HIV diagnosis (14±7 vs. 16±6 years, p=0.019) and duration of ART (10±6 vs.13±6 years, p= 0.002). 
Moreover, diabetes was significantly more prevalent in patients with a FIB4 >1.45 compared to 
those with values <1.45 (17.6% vs. 7.6%, p=0.098). Nevertheless, in the multivariate analysis, only 
duration of ART maintained this association (OR 1.008, 95%CI 1.000-1.016; p=0.04) (Table 4). 
On the other hand, APRI values >0.5 were found in 75 (48%) patients and only ALT levels were 
significantly increased in patients with evidence of significant fibrosis (78±49 vs. 56±13; OR 1.033, 
95% CI 1.015-1.510, p=0.01). In contrast to FIB4, neither the time since HIV diagnosis nor the use of 
ART or the presence of diabetes was associated with increased APRI score. Similarly to FIB4, no 
association with demographic and metabolic features was noted (Table 5). 
Interestingly, no relation was found between the presence of liver fibrosis assessed by both FIB4 
and APRI index and US evidence of steatosis. 
A small subset of patients underwent also a TE (n=19, 12.1%) and a liver biopsy (n=20, 12.8%). 
Considering a threshold stiffness value of 7.4 kPa, 4 (21.1%) patients were classified as having 
significant fibrosis, while stiffness values more than 10 Kpa were found only in 1 patient, suggesting 
more advanced liver disease. 
Despite the small number of liver biopsies, histology showed non-alcoholic fatty liver disease in 13 
(65%) patients, of who one was also diagnosed with cirrhosis. Moreover, features of drug reaction 
were present in 2 cases, while 4 patients had non-specific histological changes and 1 biopsy was 
normal. 
Discussion 
In this study, we demonstrated that persistently abnormal transaminases are fairly prevalent in 
unselected HIV mono-infected patients (156/2398, 6.5%). More importantly, 4% of these patients 
had evidence of advanced fibrosis based on simple non-invasive fibrosis tests. Despite the presence 
of persistently deranged liver tests in this group, there was inconsistent further investigation of 
these abnormalities; just 66 (42%) patients had undergone US examination and only 19 (12%) had 
a TE, despite the non-invasiveness and relatively low cost of these techniques.  
A rise in liver enzymes in HIV mono-infected individuals on ART has been previously reported. A 
cross-sectional study by Sterling et al. reported elevated transaminases in 20% of 679 patients and 
a positive association with high viral load and features of metabolic syndrome [17]. Maida et al. 
studied a cohort of 3200 individuals with long history of HIV infection and ART exposure and found 
abnormal LFTs in only 17 (0.5%) patients, of whom 10 (58.8%) had histologically advanced fibrosis 
(F3-F4) and clinically advanced liver disease. However, in this study harmful alcohol use and 
medications predisposing to steatosis were excluded [18]. On the other hand, in a prospective study 
of 2365 HIV mono-infected individuals who were followed for a 5-year period, 385 (16%) developed 
a persistent ALT elevation, which was associated with increased body mass index (BMI), high HIV 
viral load and exposure to NRTIs, in particular zidovudine and stavudine [19]. 
The underlying aetiology of increased LFTs in people who are HIV positive often remains 
unrecognized, as liver biopsy is not routinely performed. Nevertheless, many studies have indicated 
that NAFLD is more prevalent in this category of patients, potentially progressing to NASH and liver 
fibrosis. 
A histological evaluation of a cohort of 20 HIV mono-infected individuals with chronically increased 
LFTs demonstrated the presence of steatosis in 18 (60%) patients, of who 16 (88.9%) had NASH and 
13 (72.2%) had fibrosis [20]. Morse et al. biopsied a cohort of 62 patients with similar features and 
found steatosis in 45 (73%), NASH in 34 (55%) and bridging fibrosis in 11 (17%) patients respectively 
[21].  
These data are similar to our study and indicate the necessity of screening HIV positive people for 
the presence of steatosis and fibrosis, especially when LFTs are deranged. In fact, in the subgroup 
of patients who underwent a liver US, NAFLD was present in the majority of them (47/66, 71.2%). 
Moreover, even if liver biopsy was performed in only in 20 patients, histology showed non-alcoholic 
fatty liver disease in 13 (65%), and NASH in 5 (25%) patients, of who one had cirrhosis. 
The prevalence of steatosis is likely to be even higher than 70%, as ultrasound can detect steatosis 
only when more than 20-30% of hepatocytes are involved. Importantly, in our study there was no 
significant association with metabolic, anthropometric and either infection or ART related features. 
However, as US reports were available for less than a half of our cohort, this likely reflects under-
powering of the study to detect any significant associations.  
Conversely, two other studies reported a lower prevalence of NAFLD assessed by imaging 
techniques. Guaraldi et al. detected steatosis by CT scan in 37% of 225 HIV mono-infected patients, 
and found an association with cumulative NRTI exposure (OR 1.12) and obesity (OR 1.07) [22]. On 
the contrary, steatosis was present on ultrasound in 31% and at histology in 33% of 216 HIV mono-
infected patients but there was no association with either duration of HIV infection or ART, as only 
obesity (OR 2.1) and hypertriglyceridemia (OR 1.2) reached statistical significance [23]. 
Nevertheless, in both studies less than 30% of patients had deranged LFTs, thereby this possibly 
explaining the lower prevalence of steatosis compared to our findings. 
Using APRI index and FIB4 score, we classified 5 (3.2%) and 6 (3.8%) patients as potentially having 
significant and advanced fibrosis, respectively. Although TE appears to be the best non-invasive tool 
in HIV infected patients, showing an excellent accuracy for the detection of liver cirrhosis and a 
moderate accuracy for significant fibrosis [24, 25], it was available only in a small subset of the 
cohort and suggested significant fibrosis in 4 patients. On the other hand, our data suggest that 81 
(51.2%) and 105 (67.3%) patients could be excluded from having significant and advanced fibrosis 
according to APRI and FIB4, respectively. Indeed, APRI and FIB4 have a higher diagnostic accuracy in 
ruling out rather than ruling in the presence of significant/advanced fibrosis and are ideal screening 
tests as they have a negative predictive value of >90%. [14][26].  
The low prevalence of significant and advanced fibrosis based on simple non-invasive tests is 
compatible with previously published data. In a cohort of 818 HIV positive women, the majority of 
patients (86.6%) had FIB-4 values ≤1.45, while increasing FIB4 values were associated with higher 
HIV viral load [27]. Similarly, in a cohort of 225 HIV mono-infected patients, 28 were classified as not 
having fibrosis on FIB-4 [22], while in another cohort of 62 patients FIB4 ≤1.45 and >3.25 were found 
in 37 (59.7%) and 5 (%) patients respectively [21]. Conversely, a slightly higher prevalence of 8% of 
APRI values >1.5 was found in 432 HIV mono-infected patients and both diabetes and detectable 
HIV viraemia were confirmed as risk factors for significant fibrosis [28]. However, the presence of 
obesity in 50% of the cohort could have contributed to the higher prevalence of significant fibrosis.  
In our study, the duration of ART was the only factor independently associated with the presence 
of fibrosis based on FIB-4. The impact of ART on liver fibrosis is controversial as highlighted by 
conflicting reports on worsening with long term use of ART, especially didanosine or stavudine [9, 
29],  absence of significant effect [21], or even improvement following commencement of PIs [30, 
31]. Furthermore, Mendeni at al. followed a cohort of 1112 HIV mono-infected patients for 
approximately 6 years and found that progression of fibrosis, assessed by APRI and FIB4, was 
prevented by viral control by early ART, provided that didanosine use was avoided [31].  
Interestingly, in this study neither FIB4 nor APRI showed any association with metabolic features or 
increasing age. Diabetes was significantly associated with increased FIB4 values, but only in the 
univariate analysis. These data reflect the characteristics of our population, as HIV patients were 
relatively young (mean age 47 years) and both diabetes and hypertension had a low prevalence thus 
limiting the power of this study to detect any associations with fibrosis.  
This study has limitations. Firstly it is a cross sectional study, so it is not possible to define the 
dynamic process underlying the development of both steatosis and fibrosis in HIV positive patients. 
Therefore, these data should be prospectively assessed, in order to evaluate the true prognostic 
impact of hepatic steatosis and fibrosis in HIV . Secondly, the selection of patients on the basis of 
elevated transaminases could have led to an underestimation of fatty liver disease, given their lack 
of sensitivity in diagnosing NAFLD or NASH [32]. Thirdly, detection of steatosis by ultrasound could 
also have underestimated the prevalence of NAFLD, as the accuracy of this technique is suboptimal. 
In addition, an element of undisclosed alcohol abuse could have also contributed to the high 
steatosis prevalence in this cohort.  
In conclusion, the presence of liver disease is under-investigated in HIV mono-infected patients 
despite deranged LFTs. Such abnormalities are often associated with the presence of NAFLD, and 
could potentially evolve into progressive liver fibrosis. A potential role for ART in this scenario has 
yet to be determined, but it is likely that NAFLD could represent a long term toxicity of antiviral 
therapy, as suggested by the association of the length of antiviral treatment and liver fibrosis and 
evidence from other studies. A wide series of non-invasive tools for the assessment of liver fibrosis 
are currently available, therefore a non-invasive screening for the presence of NAFLD and fibrosis 
should be evaluated in the routine clinical management of HIV mono-infected patients receiving 
antiretroviral treatment. Moreover, aggressive treatment of the metabolic syndrome components 
should be undertaken in HIV positive patients with steatosis, given the well-established association 
of NAFLD with increased cardiovascular morbidity and mortality [33]. 
 
Summary box 
What is already known: 
 Liver disease is an important cause of morbidity and mortality among HIV infected 
patients, even in the absence of HCV and HBV co-infections. 
 Abnormal liver tests in HIV mono-infection is frequently reported and NAFLD is increasingly 
recognized as potential cause.  
 Non-invasive fibrosis tests are widely used for the assessment of fibrosis in liver disease, 
including HIV positive people. 
New findings: 
 Despite the high prevalence of liver tests abnormalities in HIV patients, liver disease is 
frequently under-investigated. 
 Duration of antiretroviral therapy seems to have an impact on the onset of hepatic 
steatosis and its progression to fibrosis. Therefore, NAFLD could represent a long term 
toxicity of this pharmacological treatment. 
 Simple non-invasive tests such as APRI and FIB-4 can be used for the triaging of patients for 
dedicated hepatological follow-up and/or liver biopsy.  
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Table 1. Characteristics of the cohort of HIV mono-infected patients with deranged transaminases  
Characteristics N=156 
Gender, male (%) 143 (91.7) 
Age, years 47.5 ± 8.5 
AST, IU/L 41 (22-299) 
ALT, IU/L 56 (29-372) 
GGT, U/L 74 (13-960) 
ALP, U/L 86 ± 34 
PTL, /mm3 217± 5 
Diabetes, n (%) 17 (11) 
Hypertension, n (%) 28 (18.2) 
Dyslipidaemia, n (%) 81 (51.9) 
Currently Receiving Statin, n (%) 47 (30.5) 
Currently Receiving Fenofibrate, n (%) 7 (4.5) 
Time since diagnosis, years 14 (2-30) 
Current treatment, n (%) 154 (97) 
PIs*, n (%) 41 (42.3) 
NRTIs*, n (%) 86 (88.7) 
NNRTs*, n (%) 40(41.2) 
Duration of ART years (amongst those currently 
exposed) 
11 (0-26) 
HIV-RNA, copies/ mm3>100000 0 
Virologic suppression 146 (93.6) 
CD4+, cells/mm3  683 (4-1900) 
§data expressed as mean ± SD for quantitative variables with normal distribution; data expressed 
as median (IQR) for quantitative variables without normal distribution. 
*Information on drug category available only in 97 patients (62%)* 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-
glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, platelets; PIs, protease inhibitors; NRTIs, 
nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase 
inhibitors;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Prevalence of liver disease in cohort of HIV mono-infected patients with deranged 
transaminases 
Variables N=156 
Ultrasound examinations, n (%) 66 (42.3) 
Ultrasound steatosis, n (%) 47 (71.2) 
FIB4 score  
1.45, n (%) 105 (67.3) 
1.46-3.24, n (%) 45 (28.8) 
≥3.25, n (%) 6 (3.8) 
APRI index  
0.5, n (%) 81 (51.9) 
0.51-1.49, n (%) 70 (44.9) 
≥1.5, n (%) 5 (3.2) 
Table 3. Variables associated with the presence of US liver steatosis in the cohort of HIV mono-infected patients 
 
Patient characteristics 
No steatosis 
(N= 19) 
Steatosis 
(N=47) 
Univariate 
analysis 
P value 
Multivariate analysis 
P value           OR (95% CI) 
Age, years 46.9 ± 9.5 47.9 ± 8.5 0.700   
Sex, males (%) 16(84.2) 43(91.5) 0.401   
Diabetes mellitus, n (%) 0(0) 6(12.8) 0.171   
Hypertension, n (%) 5 (26.3) 9 (19.4) 0.529   
Dyslipidaemia, n (%) 11 (57.9) 25 (53.2) 0.790   
Statin, n (%) 7 (36.8) 15 (31.9) 0.779   
Fenofibrate, n (%) 3 (15.8) 0 (0) 0.022 NS  
PLT, x103/mm3 218 ± 51 220 ± 52 0.836   
AST, IU/L 46± 14 46± 22 0.466   
ALT, IU/L 61± 15 66± 28 0.832   
ALP, U/L 92 ± 37 91± 29 0.835   
GGT, U/L 194 ± 273 97 ± 86 0.428   
Duration since diagnosis, years 15 ± 8 14 ± 7 0.451   
Duration of treatment, years 12± 6 16± 6 0.729   
PIs, n (%) 4(21) 13(27.7) 1.000   
NRTIs, n (%) 11 (57.9) 32 (68.1) 1.000   
NNRTs, n (%) 6 (31.6) 14 (29.8) 0.737   
Virologic suppression, n (%) 18 (94.7) 44 (93.6) 1.000   
CD4+ <200/mm3, n (%) 0 0 -   
FIB4 >1.45, n (%) 7 (36.8) 17 (36.2) 1.000   
APRI >0.5, n (%) 10 (52.6) 25 (53.2) 1.000   
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, 
platelets;  PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, 
ultrasound. 
 
 
 
 
 
 
 
Table 4. Variables associated with the presence of liver fibrosis assessed by FIB4 in the whole cohort of HIV mono-infected patients. 
 
Patient characteristics 
FIB4 ≤1.45 
(N= 105) 
FIB4 >1.46 
(N=51) 
Univariate 
analysis 
P value 
Multivariate analysis 
P value                    OR (95% CI) 
Age, years - - -   
Sex, males (%) 94 (89.5) 49 (96.1) 0.224   
Diabetes mellitus, n (%) 8 (7.6) 9 (17.6) 0.098 NS  
Hypertension, n (%) 16 (15.2) 12 (23.5) 0.268   
Dyslipidaemia, n (%) 58 (55.2) 23 (45.1) 0.305   
Statins, n (%) 32 (30.5) 15 (29.4) 1.000   
Fenofibrate, n (%) 5 (4.8) 2 (4) 1.000   
PLT, x103/mm3 - - -   
ALT, IU/L - - -   
AST, IU/L - - -   
ALP, U/L 88 ± 33 80 ± 31 0.138   
GGT, U/L 99 ± 123 156 ± 191 0.104   
Time since HIV diagnosis, years 14 ± 7 16 ± 6 0.019 NS  
Duration of ART, years 10 ± 6 13 ± 6 0.002 0.041 1.008 (1.000-1.016) 
PIs, n (%) 23 (21.9) 18 (35.3) 0.202   
NRTIs, n (%) 55 (52.4) 31 (60.8) 1   
NNRTs, n (%) 28 (26.7) 12 (23.5) 0.391   
Virologic suppression, n (%) 98 (9.3) 48 (94.1) 1.000   
CD4+ <200/mm3, n (%) 1 (0.9) 2 (3.9) 0.249   
US steatosis, n (%) 30 (28.6) 17(33.3) 1   
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, 
platelets;  PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, 
ultrasound. 
 
 
 
 
 
 
 
Table 5. Variables associated with the presence of liver fibrosis assessed by APRI index in the whole cohort of HIV mono-infected patients. 
 
Patient characteristics 
APRI ≤0.5 
(N= 81) 
APRI>0.51 
(N=75) 
Univariate 
analysis 
P value 
Multivariate analysis 
P value                      OR (95% CI) 
Age, years 47.1 ± 8.3 47.9 ± 8.8 0.57   
Sex, males (%) 73 (89.5) 70 (96.1) 0.568   
Diabetes mellitus, n (%) 9 (7.6) 8 (17.6) 1   
Hypertension, n (%) 14 (15.2) 14 (23.5) 0.836   
Dyslipidaemia, n (%) 45 (55.2) 36 (45.1) 0.423   
PLT, x103/mm3 - - -   
Statin, n (%) 23 (30.5) 24 (29.4) 0.601   
Fenofibrate, n (%) 4 (4.9) 3 (4) 1.000   
ALT, IU/L 56 ± 13 78 ± 49 0.001 0.01 1.033 (1.015-1.510) 
AST, IU/L - - -   
ALP, U/L 87 ± 28 85 ± 37 0.751   
GGT, U/L 85 ± 64 153 ± 201 0.223   
Duration of infection, years 15 ± 7 14 ± 7 0.425   
Duration of treatment, years 11 ± 6 11 ± 6 0.767   
PIs, n (%) 19 (23.4) 22 (29.3) 0.311   
NRTIs, n (%) 45 (55.5) 41 (54.7) 1.000   
NNRTs, n (%) 20 (24.7) 20 (26.7) 0.685   
CD4+ <200/mm3, n (%) 1 (0.9) 2 (3.9) 0.608   
Virologicalsuppression, n (%) 76 (93.8) 70 (93.3) 1.000   
US steatosis, n (%) 22 (28.6) 25 (33.3) 1.000   
 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, 
platelets;  PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, 
ultrasound. 
 
 
 
 
 
  
  
 
